Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal C⦠(NCT05953662) | Clinical Trial Compass
Active ā Not RecruitingNot Applicable
Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer
China500 participantsStarted 2023-09-01
Plain-language summary
Colorectal cancer is the third most common malignant tumor. Radical resection is the mainstay of treatments for non-metastatic colorectal cancer. In case of traditional laparoscopic surgery, inexperienced assistants are likely to cause side injuries and interfere surgeon due to limited operating space. Reduced-port laparoscopic surgery has only 3 ports for surgeon and observer, and the surgeon completes the surgery independently, which increases the difficulty of the operation. However, reduced-port laparoscopy has some potential advantages and applications. Reduced-port laparoscopic surgery avoids the prolongation of the operation time and parainjury caused by inexperienced assistant. Reduced-port laparoscopy reduces some surgical incisions, resulting in less pain and faster recovery. Reduced-port laparoscopy also reduces the consumables, human resources and medical expenses. This study aims to evaluate the curative effect and safety of reduced-port laparoscopic surgery versus conventional laparoscopic surgery for resectable colorectal cancer.
Who can participate
Age range18 Years ā 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age 18-80 years old;
ā. Pathological diagnosis of colorectal adenocarcinoma (including high, medium and low-differentiated adenocarcinoma, excluded: mucinous adenocarcinoma, signet ring cell carcinoma);
ā. Eastern Cooperative Oncology Group (ECOG) is 0-1 points;
ā. Chest, whole abdomen, pelvic enhanced CT confirm colon or upper rectal cancer, without distant metastasis;
ā. No other multiple primary tumors;
ā. No organ dysfunction;
ā. The patient and his/her family are able to understand the study protocol and are willing to participate in the study and sign informed consent.
Exclusion criteria
ā. Age \< 18, or \> 80 years old;
ā. Combined with simultaneous or heterogeneous (within 5 years) malignant tumors;
ā
What they're measuring
1
DFS rate
Timeframe: 1 year
Trial details
NCT IDNCT05953662
SponsorSixth Affiliated Hospital, Sun Yat-sen University